Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Tigermed Consulting CoFRA:5HZ1 +2.29%81 5-Year Yield-on-Cost % is 0.51 as of Aug. 12, 2026, which is 12% below its 10-year median of 0.58. GuruFocus rates FRA:5HZ1 with a GF Score™ of 81/100 and a GF Value™ of €5.73 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Hangzhou Tigermed Consulting Co ranks worse than 87.3% on this metric.
The historical rank and industry rank for Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:5HZ1'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.2 Med: 0.58 Max: 2.27
Current: 0.51
During the past 13 years, Hangzhou Tigermed Consulting Co's highest Yield on Cost was 2.27. The lowest was 0.20. And the median was 0.58.
FRA:5HZ1's 5-Year Yield-on-Cost % is ranked worse than 87.3% of 63
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.42
vs FRA:5HZ1: 0.51
Hangzhou Tigermed Consulting Co (FRA:5HZ1) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Hangzhou Tigermed Consulting Co 5-Year Yield-on-Cost % Related Terms
FRA:5HZ1 vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % falls into.
Hangzhou Tigermed Consulting Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a 5-Year Yield-on-Cost % of 0.51 as of Aug. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Hangzhou Tigermed Consulting Co and its competitors. This is 12% below median its historical median of 0.58. Over the past decade, Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % has ranged from 0.20 to 2.27. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #55 out of 63 companies in the Medical Diagnostics & Research industry, placing it in the top 87.3%.
Is Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % too high?
Hangzhou Tigermed Consulting Co's current 5-Year Yield-on-Cost % of 0.51 is 12% below median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 2.27. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.42. Hangzhou Tigermed Consulting Co's value of 0.51 is 78.9% below this industry median. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #55 out of 63 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #55 out of 63 companies for 5-Year Yield-on-Cost %. This places Hangzhou Tigermed Consulting Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.42. Hangzhou Tigermed Consulting Co's value of 0.51 is 78.9% below this benchmark. Historically, Hangzhou Tigermed Consulting Co's own 5-Year Yield-on-Cost % has ranged from 0.20 to 2.27 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 2.42, Hangzhou Tigermed Consulting Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.42, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Tigermed Consulting Co's current 5-Year Yield-on-Cost % of 0.51 is 78.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Hangzhou Tigermed Consulting Co and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Tigermed Consulting Co's current 5-Year Yield-on-Cost % is 0.51, which is 12% below median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (FRA:5HZ1) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.73, compared to a current price of €4.46 — trading 22.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.51, which is 12% below median its 10-year median of 0.58 and 78.9% below the Medical Diagnostics & Research industry median of 2.42. Hangzhou Tigermed Consulting Co's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current 5-Year Yield-on-Cost % is 0.51 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of €4.46 is trading 22.2% below its estimated GF Value™ of €5.73.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.
Key valuation signals for FRA:5HZ1:
5-Year Yield-on-Cost %: 0.51 (12% below median its 10-year median of 0.58)
GF Value™: €5.73 vs. price of €4.46 (22.2% below fair value)
Industry Position: 78.9% below the Medical Diagnostics & Research median (#55 of 63)
No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
81GF Score
Get the complete analysis for FRA:5HZ1
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HZ1 has been successfully added to your 
